AVID RADIOPHARMS INC
SpecialtyAVID RADIOPHARMS INC is a specialty pharmaceutical company focused on Neurology. Key products include TAUVID.
FDA Novel Drug Designations
(2020)See 1 novel approval →
AVID RADIOPHARMS INC's Key Drugs
AVID RADIOPHARMS INC's core commercial portfolio centers on TAUVID, AMYVID, spanning Neurology — its most strategically important drugs approved in the last 15 years.
AVID RADIOPHARMS INC's Recent FDA Approvals
New NDA/BLA approvals for AVID RADIOPHARMS INC over the last two years — novel drugs only, excluding generics and label supplements.
AVID RADIOPHARMS INC's Therapeutic Areas
AVID RADIOPHARMS INC's approved drugs and pipeline span 1 therapeutic area, led by Neurology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
AVID RADIOPHARMS INC's Top Competitors
AVID RADIOPHARMS INC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
AVID RADIOPHARMS INC Pipeline Snapshot
Active clinical trials for AVID RADIOPHARMS INC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • TAUVID leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling